{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant that does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.","groups":[{"description":"Participants with non-follicular iNHL with MZL as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity or withdrawal from the study whichever occurred first.","id":"OG000","title":"MZL: Umbralisib"},{"description":"Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.","id":"OG001","title":"WM: Umbralisib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included all enrolled participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment up to end of study (up to approximately 4.2 years)","title":"Number of Participants With at Least One Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}